Could a malaria drug boost chemo for pancreatic cancer?
NCT ID NCT04911816
First seen Apr 28, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This study tests whether adding hydroxychloroquine (a malaria drug) to standard chemotherapy before surgery can improve outcomes for people with resectable pancreatic cancer. About 40 participants will receive the drug combo, then undergo surgery to remove their tumor. The goal is to find a safe dose and see if the treatment shrinks tumors enough to improve surgical results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PANCREAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West Virginia University Cancer Institute Mary Babb Randolph Cancer Center
RECRUITINGMorgantown, West Virginia, 26506, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hydroxychloroquine (Plaquenil) plus mFOLFIRINOX chemotherapy
What this could lead to
If it works, this could point toward a more effective treatment approach for resectable pancreatic cancer, potentially improving surgical outcomes and survival.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply broadly. Hydroxychloroquine can cause side effects like vision problems and heart issues, and the combination may not improve outcomes over standard chemo alone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.